# US 6,727,243 B1 · Compositions comprising cefuroxime axetil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,243 B1
- Document ID: US6727243B1
- Status: Granted
- Kind: B1
- Application number: 09/445,741
- Filed: 1999-12-10
- Granted: 2004-04-27
- Earliest claimed: 1998-11-26
- Assignees: Biochemie Gesellschaft m.b.H.
- Inventors: Herwig Jennewein; Johannes Raneburger
- Web page: https://patentgrep.com/patent/US6727243B1

## CPC

- A61K 9/143: {with inorganic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid, e.g., in the form of a solid dispersion on a carrier, e.g., useful for the production of pharmaceutical compositions comprising cefuroxime axetil as an active ingredient and use of cefuroxime axetil in the manufacture of an oral dosage form which does not exhibit an adverse food effect.

## Claims

### Claim 1

Cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid comprising cefuroxime axetil in the form of a solid solution dissolved in a polymer.

### Claim 2 (depends on 1)

Cefuroxime axetil according to claim 1, wherein the weight ratio of cefuroxime axetil:polymer is 1:0.15 to 1:06.

### Claim 3 (depends on 1)

A pharmaceutical compositions comprising a pharmaceutically effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid according to claim 1 as an active ingredient in combination with pharmaceutically acceptable excipient.

### Claim 4 (depends on 1)

A pharmaceutical composition according to claim 1, in the form of a pharmaceutical dosage form wherein said dosage form effects at least 60% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 15 minutes and/or at least 75% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 45 minutes; when said dosage form of cefuroxime axetilis tested as set forth in USP test <711> in a USP-2 apparatus under conditions at least as stringent as the following: 900 ml 0.07 N hydrochloric acid, 37° C. with paddles turning at 55 rpm.

### Claim 5 (depends on 1)

A dry powder for oral administration comprising an effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid according to claim 1 as an active ingredient and pharmaceutically acceptable excipient.

### Claim 6 (depends on 5)

A dry powder according to claim 5 in a container, containing cefuroxime axetil in an amount corresponding to an effective amount of cefuroximc.

### Claim 7 (depends on 5)

A syrup/suspenion for oral administration comprising a dry powder according to claim 5 which is reconstituted with an aqueous liquid.

### Claim 8 (depends on 7)

A suspension/syrup according to claim 7 for oral administration comprising an effective amount of cefuroxime axetil wherein glucose and/or fructose are in highly concentrated solution.

### Claim 9 (depends on 1)

A tablet for oral administration comprising an effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid as an active ingredient according to claim 1, and pharmaceutically acceptable excipient.

### Claim 10 (depends on 9)

A tablet according to claim 9 which is film-coated.

### Claim 11 (depends on 1)

A film-coated tablet comprising cefuroxime axetil according to claim 1 as an active ingredient and a film coat(ing), a rupture time of the film coat(ing) being 40 seconds and more when measured by a rupture test, wherein the tablet is placed in a beaker of still 0.07 M hydrochloric acid at 37°, the rupture being measured as the time which elapses before the core of the tablet becomes invisible to the naked eye through the ruptured film coat; wherein said film coated tablet effects at least 60% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 15 minutes, when the film-coated tablet of cefuroxime axetil is tested as set forth in USP test <711> in a USP-2 apparatus under conditions at least as stringent as the following: 900 mL 0,07 N hydrochloric acid, 37° C. with paddles turning at 55 rpm.

### Claim 12 (depends on 1)

A packaging for a pharmaceutical composition comprising cefuroxime axetil according to claim 1 as an active ingredient in the form of film-coated tablets comprising an effective amount of cefuroxime axetil, which comprises the packaging lacks sealing against moisture attack and the film-coated tablets lack sealing against moisture attack.

### Claim 13 (depends on 9)

A process for the production of a tablet according to claim 9 comprising an effective amount of cefuroxime axetilin non-gelatinous form on contact with an aqueous liquid as an active ingredient, which comprises compressing a granulate of cefuroxime axetil and a polymer and/or an adsorbent wherein cefuroxime axetil is in non-gelatinous form on contact with an aqueous liquid and one or more pharmaceutically acceptable excipients in mixture with one or more pharmaceutically acceptable excipients and, if desired, film coating.

### Claim 14 (depends on 1)

An oral dosage form of cefuroxime axetil according to claim 1 which is in the form of a tablet which is administrable to a mammal that is in the fastened state and which exhibits no adverse food effect, which comprises an effective amount of cefuroxime axetil and pharmaceutically acceptable excipient.

### Claim 15 (depends on 1)

An oral dosage form of cefuroxime axetil according to claim 1 which is in the form of a dry powder or which is in the form of a suspension/syrup and which is administrable to a mammal that is in the fastened state and which exhibits no adverse food effect, which comprises an effective amount of cefuroxime axetil and pharmaceutically acceptable excipient.

### Claim 16 (depends on 14)

An oral dosage form according to claim 14 which effects at least 60% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 15 minutes and/or at least 75% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 45 minutes; when a dosage form of cefuroxime axetilis tested as set forth in USP test <711> in a USP-2 apparatus under conditions at least as stringent as the following: 900 ml 0.07 N hydrochloric acid, 37° C. with paddles turning at 55 rpm.

### Claim 17 (depends on 1)

A process for the production of granulates comprising cefuroxime axetil according to claim 1, in which the active ingredient cefuroxime axetil is present in an activated form so that it no longer has a tendency to form a gel when in contact with aqueous media, characterized in that granulation is carried out under addition of a polymer or an insoluble adsorbent.

### Claim 18

Cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid comprising cefuroxime axetil in the form of a solid dispersion on an adsorbent.

### Claim 19 (depends on 18)

A pharmaceutical compositions comprising a pharmaceutically effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid according to claim 18 as an active ingredient in combination with pharmaceutically acceptable excipient.

### Claim 20 (depends on 1)

A pharmaceutical composition according to claim 1, in the form of a pharmaceutical dosage form wherein said dosage form effects at least 60% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 15 minutes when said dosage form of cefuroxime axetil is tested as set forth in USP test <711> in a USP-2 apparatus under conditions at least as stringent as the following: 900 mL, 0,07 N hydrochloride acid, 37° C. with paddles turning at 55 rpm.

### Claim 21 (depends on 18)

A dry powder for oral administration comprising an effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid according to claim 18 as an active ingredient and pharmaceutically acceptable excipient.

### Claim 22 (depends on 18)

A tablet for oral administration comprising an effective amount of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid as an active ingredient according to claim 18, and pharmaceutically acceptable excipient.

### Claim 23 (depends on 18)

A film-coated tablet comprising cefuroxime axetil according to claim 18 as an active ingredient and a film coat(ing), a rupture time of the film coat(ing) being 40 seconds and more when measured by a rupture test, wherein the tablet is placed in a beaker of still 0.07 M hydrochloric acid at 37°, the rupture being measured as the time which elapses before the core of the tablet becomes invisible to the naked eye through the ruptured film coat; wherein said film coated tablet effects at least 60% (Q-value) dissolution of the labeled amount of cefuroxime axetil within 15 minutes, when the film-coated tablet of cefuroxime axetil is tested as set forth in USP test <711> in a USP-2 apparatus under conditions at least as stringent as the following: 900 mL 0,07 N hydrochloric acid, 37° C. with paddles turning at 55 rpm.

### Claim 24

Cefuroxime axctil in non-gelatinous form on contact with an aqueous liquid which comprises cefuroxime axetil in the form of a solid solution dissolved in a polymer in combination with cefuroxime axetil in the form of a solid dispersion on an adsorbent.

### Claim 25

A granulate of cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid comprising cefuroxime axetil dissolved in a polymer and/or an adsorbent; and pharmaceutically acceptable excipient.

### Claim 26

A process for the production of cefuroxime axetil in non-gelatinous form on contact with an aqueous liquid comprising dissolving or suspending cefuroxime axetil and a polymer in an organic solvent which is able to form a non-gelatinous solid together with cefuroxime axetil and/or a carrier which is able to form a surface solid dispersion with cefuroxime axetil in the organic solvent and removing the solvent.

### Claim 27

A process for the production of a granulate wherein cefuroxime axetil is in non-gelatinous form on contact with an aqueous liquid, comprising removing solvent from a suspension or solution containing
cefuroxime axetil and a polymer which is able to form a non-gelatinous solid on contact with an aqueous liquid; and adding optionally, pharmaceutically acceptable excipients.

### Claim 28

A process for the production of a granulate wherein cefuroxime axetil is in non-gelatinous form on contact with an aqueous liquid, comprising removing solvent from a suspension or solution containing cefuroxime axetil and an adsorbent which is able to form a surface solid dispersion with cefuroxime axetil; and optionally adding pharmaceutically acceptable excipients.
